High dose of Wegovy drives weight loss to 19% A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation

#obesitymanagement #weighloss #obesity #Wegovy #ObesityActionCoalition #NovoNordisk #GLP1agonist #weightloss #obesitytrial #EliLilly #Lilly #TheLancetDiabetesandEndocrinology #STEPUPT2D #highdosesemaglutide #dualGIPGLP1agonist #Zepbound #tirzepatide #oralGLP1agonist
zurl.co/GCtWR